Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 21, 2026, 8:34 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 169–192 of 341 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Anti-Inflammatory Agents Clear all
Terminated Phase 3 Interventional Results available

The Safety and Tolerability of Budesonide Foam in Participants With Active Ulcerative Proctitis or Proctosigmoiditis

NCT01349673
View directory record Official record
Conditions
Proctitis, Proctosigmoiditis
Interventions
Budesonide Foam
Drug
Lead sponsor
Bausch Health Americas, Inc.
Industry
Eligibility
18 Years and older
Enrollment
114 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 14, 2019 · Synced Oct 21, 2026, 8:34 PM EDT
Completed No phase listed Observational Results available

Exploring the Anti-inflammatory Properties of Cannabis and Their Relevance to Insulin Sensitivity

NCT04114903
View directory record Official record
Conditions
Type 2 Diabetes, Obesity, Cannabis Use, Insulin Sensitivity
Interventions
Study A: Single use of cannabis flower product, Study B: Ad libitum cannabis use for four weeks or no cannabis use
Other
Lead sponsor
University of Colorado, Boulder
Other
Eligibility
21 Years to 40 Years
Enrollment
233 participants
Timeline
2019 – 2024
U.S. locations
1
States / cities
Boulder, Colorado
Source: ClinicalTrials.gov public record
Updated Aug 6, 2026 · Synced Oct 21, 2026, 8:34 PM EDT
Terminated Phase 2 Interventional Results available

Denintuzumab Mafodotin (SGN-CD19A) Combined With RCHOP or RCHP Versus RCHOP Alone in Diffuse Large B-Cell Lymphoma or Follicular Lymphoma

NCT02855359
View directory record Official record
Conditions
Diffuse, Large B-Cell, Lymphoma, Follicular Lymphoma, Grade 3b, Transformed Lymphoma / DLBCL
Interventions
denintuzumab mafodotin, rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone
Drug
Lead sponsor
Seagen Inc.
Industry
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
34
States / cities
Birmingham, Alabama • Jonesboro, Arkansas • Duarte, California + 31 more
Source: ClinicalTrials.gov public record
Updated Mar 11, 2019 · Synced Oct 21, 2026, 8:34 PM EDT
Recruiting Not applicable Interventional

Effect of Anti-inflammatory Diet in Systemic Lupus Erythematous

NCT07713940
View directory record Official record
Conditions
Systemic Lupus Erthematosus (SLE)
Interventions
anti-inflammatory diet
Dietary Supplement
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated Jul 20, 2026 · Synced Oct 21, 2026, 8:34 PM EDT
Terminated Phase 4 Interventional

ADVAIR DISKUS® (Fluticasone Propionate/Salmeterol) Inhaler Versus SEREVENT DISKUS® (Salmeterol) Inhlaer On Inflammatory Cells And Markers In Chronic Obstructive Pulmonary Disease. ADVAIR DISKUS® and SEREVENT DISKUS® Inhalers Are Trademarks of the GSK Group of Companies.

NCT00346749
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
Salmeterol, Fluticasone Propionate/Salmeterol Combination Product
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
40 Years and older
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
11
States / cities
Birmingham, Alabama • Los Angeles, California • San Diego, California + 7 more
Source: ClinicalTrials.gov public record
Updated Oct 28, 2016 · Synced Oct 21, 2026, 8:34 PM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

Saffron as Anti Inflammatory Agent In Patients With Inflammatory Bowel Disease

NCT04749576
View directory record Official record
Conditions
Ulcerative Colitis
Interventions
saffron supplement for IBD
Dietary Supplement
Lead sponsor
Howard University
Other
Eligibility
18 Years to 80 Years
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2023
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Feb 11, 2021 · Synced Oct 21, 2026, 8:34 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Effects of Topical SLPI on Skin Wounds

NCT00005569
View directory record Official record
Conditions
Healthy, Wound Healing
Interventions
SLPI (Secretory Leukocyte Protease Inhibitor)
Drug
Lead sponsor
National Institute of Dental and Craniofacial Research (NIDCR)
NIH
Eligibility
Not listed
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2000 – 2003
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 4, 2008 · Synced Oct 21, 2026, 8:34 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Ibuprofen Inhibits Human Sweet Taste

NCT06291337
View directory record Official record
Conditions
Treatment of Sweet Taste Receptors Without or With an Oral Rinse of Ibuprofen Solution in Healthy Participants, Treatment of Sweet Taste Receptors Without or With an Oral Rinse of Naproxen Solution in Healthy Participants
Interventions
Inhibition of Sweet Taste by Ibuprofen Oral Rinses, Inhibition of Sweet Taste by Naproxen Oral Rinses
Drug
Lead sponsor
Rutgers, The State University of New Jersey
Other
Eligibility
18 Years to 70 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2023
U.S. locations
1
States / cities
New Brunswick, New Jersey
Source: ClinicalTrials.gov public record
Updated Mar 4, 2024 · Synced Oct 21, 2026, 8:34 PM EDT
Not listed Phase 2 Interventional

Curcumin and Yoga Therapy for Those at Risk for Alzheimer's Disease

NCT01811381
View directory record Official record
Conditions
Mild Cognitive Impairment
Interventions
Curcumin, aerobic yoga, non aerobic yoga, Placebo
Drug · Behavioral · Dietary Supplement
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
50 Years to 90 Years
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2020
U.S. locations
1
States / cities
West Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Sep 17, 2020 · Synced Oct 21, 2026, 8:34 PM EDT
Not listed Phase 4 Interventional Accepts healthy volunteers

Pain Control After Lumbar Spine Fusion

NCT06484192
View directory record Official record
Conditions
Spine Fusion, NSAID (Non-Steroidal Anti-Inflammatory Drug), Postoperative Pain
Interventions
Naproxen 500 Mg, Ketorolac, OxyCODONE 5 mg Oral Tablet, Metaxalone 800 MG
Drug
Lead sponsor
Rothman Institute Orthopaedics
Other
Eligibility
18 Years and older
Enrollment
428 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 3, 2024 · Synced Oct 21, 2026, 8:34 PM EDT
Recruiting Phase 1Phase 2 Interventional

Phase I/II Study of Pacritinib, A JAK2/IRAK1/CSF1R Inhibitor, in Refractory Chronic Graft-Versus-Host Disease (cGVHD) After Allogeneic Hematopoietic Stem Cell Transplantation (HSCT)

NCT05531786
View directory record Official record
Conditions
Graft vs Host Disease
Interventions
Pacritinib
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 120 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
2
States / cities
Miami, Florida • Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 28, 2026 · Synced Oct 21, 2026, 8:34 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Delaying Alzheimer Disease Symptoms With Anti-Inflammatory Drugs

NCT00065169
View directory record Official record
Conditions
Alzheimer Disease, Dementia
Interventions
Celecoxib
Drug
Lead sponsor
University of California, Los Angeles
Other
Eligibility
40 Years to 90 Years
Enrollment
138 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2000 – 2005
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Mar 2, 2020 · Synced Oct 21, 2026, 8:34 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Aspirin for the Treatment of Nonalcoholic Fatty Liver Disease

NCT04031729
View directory record Official record
Conditions
Nonalcoholic Fatty Liver, Nonalcoholic Steatohepatitis
Interventions
Aspirin 81 mg, Placebo oral tablet
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 70 Years
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 24, 2024 · Synced Oct 21, 2026, 8:34 PM EDT
Active, not recruiting Phase 3 Interventional Results available

A Study Comparing Upadacitinib (ABT-494) to Placebo and to Adalimumab in Adults With Rheumatoid Arthritis Who Are on a Stable Dose of Methotrexate and Who Have an Inadequate Response to Methotrexate

NCT02629159
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Placebo for Adalimumab, Adalimumab, Placebo for Upadacitinib, Upadacitinib
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years and older
Enrollment
1,629 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2027
U.S. locations
109
States / cities
Birmingham, Alabama • Mesa, Arizona • Peoria, Arizona + 83 more
Source: ClinicalTrials.gov public record
Updated Aug 5, 2025 · Synced Oct 21, 2026, 8:34 PM EDT
Withdrawn Phase 2 Interventional

Anti-Inflammatory Lipid Mediators in Asthma

NCT03680976
View directory record Official record
Conditions
Asthma
Interventions
CXA-10, Placebo
Drug
Lead sponsor
Sally E. Wenzel MD
Other
Eligibility
18 Years to 65 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 2021
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 21, 2018 · Synced Oct 21, 2026, 8:34 PM EDT
Completed Phase 3 Interventional

Efficacy and Safety APT-1011 in Adult Subjects With Eosinophilic Esophagitis (EoE) (FLUTE-2)

NCT04281108
View directory record Official record
Conditions
Eosinophilic Esophagitis
Interventions
APT-1011, Placebo oral tablet, Esophagogastroduodenoscopy
Drug · Procedure
Lead sponsor
Ellodi Pharmaceuticals, LP
Industry
Eligibility
18 Years and older
Enrollment
143 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
48
States / cities
Anniston, Alabama • Dothan, Alabama • Mobile, Alabama + 43 more
Source: ClinicalTrials.gov public record
Updated Jun 12, 2023 · Synced Oct 21, 2026, 8:34 PM EDT
Recruiting Not applicable Interventional

Tailored Anti-Inflammatory (A-I) Diet for Americans With Ulcerative Colitis (UC)

NCT06784323
View directory record Official record
Conditions
Ulcerative Colitis
Interventions
Catered diet, Diet guidance sessions, Dietary counseling, Feedback sessions
Behavioral
Lead sponsor
University of Miami
Other
Eligibility
16 Years to 75 Years
Enrollment
122 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Mar 30, 2026 · Synced Oct 21, 2026, 8:34 PM EDT
Not yet recruiting Not applicable Interventional

NaviCam Patency Capsule to Verify Gastrointestinal Patency

NCT07649720
View directory record Official record
Conditions
Intestinal Stricture, Crohn Disease, NSAID (Non-Steroidal Anti-Inflammatory Drug) Induced Enteropathy, Abdominal Pain
Interventions
NaviCam Patency Capsule
Device
Lead sponsor
AnX Robotica Corp.
Industry
Eligibility
22 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Downers Grove, Illinois
Source: ClinicalTrials.gov public record
Updated Jun 16, 2026 · Synced Oct 21, 2026, 8:34 PM EDT
Completed Phase 2 Interventional

Curcumin in Patients With Mild to Moderate Alzheimer's Disease

NCT00099710
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
Curcumin C3 Complex
Dietary Supplement
Lead sponsor
John Douglas French Foundation
Other
Eligibility
50 Years and older
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2007
U.S. locations
1
States / cities
Westwood, Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Dec 3, 2009 · Synced Oct 21, 2026, 8:34 PM EDT
Recruiting Phase 4 Interventional

Anti-Inflammatory Challenge in Schizophrenia

NCT05823532
View directory record Official record
Conditions
Schizophrenia
Interventions
Infliximab, Placebo
Drug
Lead sponsor
Emory University
Other
Eligibility
18 Years to 55 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
2
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Jun 3, 2026 · Synced Oct 21, 2026, 8:34 PM EDT
Completed Phase 1 Interventional

Effect of an Anti-Inflammatory Drug on Gut Mucosa in HIV Infected Patients

NCT00069498
View directory record Official record
Conditions
HIV Infections
Interventions
5-aminosalicylic acid
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 65 Years · Male only
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1999
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated May 25, 2007 · Synced Oct 21, 2026, 8:34 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Non-steroidal Anti-inflammatory Affect on Kidneys in Endurance Distances

NCT02272725
View directory record Official record
Conditions
Acute Kidney Injury, Exercise-associated Hyponatremia, Perceived Exertion
Interventions
Ibuprofen, Placebo
Drug
Lead sponsor
Stanford University
Other
Eligibility
18 Years to 75 Years
Enrollment
91 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2017
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Dec 12, 2018 · Synced Oct 21, 2026, 8:34 PM EDT
Completed Phase 2 Interventional

Evaluation of the Utility of Minocycline as an Anti-Inflammatory Agent in the Treatment of Asthma

NCT00456677
View directory record Official record
Conditions
Asthma
Interventions
minocycline, Placebos
Drug
Lead sponsor
State University of New York - Downstate Medical Center
Other
Eligibility
18 Years to 75 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1996 – 2007
U.S. locations
1
States / cities
Brooklyn, New York
Source: ClinicalTrials.gov public record
Updated Apr 18, 2017 · Synced Oct 21, 2026, 8:34 PM EDT
Not yet recruiting Phase 1Phase 2 Interventional

The Effect of Dexamethasone on Short Term Patient Response: IV vs Oral Administration

NCT07832110
View directory record Official record
Conditions
Post Operative Pain, Acute, Periodontitis
Interventions
Dexamethasone IV injection, Dexamethasone Capsule, Placebo IV administration, Placebo capsule
Drug · Other
Lead sponsor
The University of Texas Health Science Center at San Antonio
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Sep 21, 2026 · Synced Oct 21, 2026, 8:34 PM EDT